## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  KENYON LAWRENCE A						2. Issuer Name <b>and</b> Ticker or Trading Symbol Oncobiologics, Inc. [ ONS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
						Oncoologics, me. [ Ono ]									X	Direc	ctor		10% Owner	
					-									_			er (give title		Other (specify	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)										,		below)			
C/O ONO	COBIOLO	GICS, INC.			09/	09/18/2018									CEO, Pres, CFO, Treas & Secy					
7 CLARKE DRIVE																				
/ CLARKE DRIVE			4 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								- 6	6. Individual or Joint/Group Filing (Check Applicable							
(Street)					·   4. "	Amei	iumeni,	, Dale	or Origin	iai File	tu (IVIOIIIII/Da	ау/ 16	earj		ine)	iuai u	i John Group	rilling (C	IIECK A	phiicable
CRANBI	JRY N	ī (	08512												X	Form	n filed by One	e Reportin	g Pers	on
Cidirib	J1(1 1)		30312													Form	n filed by Mor	e than Or	ne Rep	orting
(0:1.)	(0		·-· \													Pers	on			
(City)	(S	tate) (	Zip)																	
		Tabl	le I - N	on-Deriv	ative	Sec	uritie	s Ac	quired	d, Di	sposed o	f, o	or Bei	nefici	ally O	wne	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day)					Execution Date,					s Acquired (A) or of (D) (Instr. 3, 4 a			nd 5) Secur Benet		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount (A) or (D)		Price	-	Transaction(s) (Instr. 3 and 4)				(111501.4)	
Common Stock 09/18/20					2018	018		S		10,100 <sup>(1)</sup> D \$		\$0.8	72 <sup>(2)</sup> 57,213 <sup>(3)</sup>		D					
		Та	able II								osed of,					ned				
				(e.g., p	uts, c	alls,	warr	ants,	optio	ns, c	convertib	le s	secur	ities)						
Derivative Conversion		Date (Month/Day/Year)	Executi if any	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerc tion Da n/Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		f g	8. Price Derivati Security (Instr. 5)		9. Number o derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form Direct or Ind (I) (In	t (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Titl	or Nu of	ımber						

## **Explanation of Responses:**

- 1. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.855 \$0.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- 3. Includes 21,739 shares of the Issuer's common stock subject to RSUs that will vest on 9/15/2019, subject to continued service through such date.

## Remarks:

/s/ Lawrence Kenyon

\*\* Signature of Reporting Person

09/18/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.